CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531

导出原文传递

翻译打印收藏纠错

作者： Lamba, Jatinder K. ^[1] ; Chauhan, Lata ^[2] ; Shin, Miyoung ^[3] ; Loken, Michael R. ^[4] ; Pollard, Jessica A. ^[5] ; Wang, Yi-Cheng ^[6] ; Ries, Rhonda E. ^[7] ; Aplenc, Richard ^[8] ; Hirsch, Betsy A. ^[9] ; Raimondi, Susana C. ^[10] ; Walter, Roland B. ^[11] ; Bernstein, Irwin D. ; Gamis, Alan S. ; Alonzo, Todd A. ; Meshinchi, Soheil

作者单位： Maine Med Ctr, Portland, ME 04102 USA ^[1] Univ Southern Calif, Los Angeles, CA USA ^[2] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA ^[3] Hematol Inc, Seattle, WA USA ^[4] St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA ^[5] Childrens Mercy Hosp & Clin, Kansas City, MO USA ^[6] Univ Florida, Gainesville, FL 32610 USA ^[7] Childrens Oncol Grp, Monrovia, CA USA ^[8] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA ^[9] Univ Minnesota, Minneapolis, MN USA ^[10] Univ Washington, Seattle, WA 98195 USA ^[11]

发布时间 2018-10-31

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Journal of Clinical Oncology

2017年35卷23期

2674-2682页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531

Journal of Clinical Oncology

相似文献

Journal of Clinical Oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531

Journal of Clinical Oncology

相似文献

Journal of Clinical Oncology

相关期刊

检索历史清除